NOXXON Pharma NV has secured financing of up to €14.2 million in convertible bonds enabling it to continue the clinical development of its RNA oligonucleotide drugs for cancer. The convertible bond agreement is with Atlas Special Opportunities LLC. The full financing agreement, if drawn in total, will allow the Germany-based company to finance its activities to the beginning of 2022, including the completion of an ongoing trial in patients with newly diagnosed brain cancer.
